Royalty Report: Drugs, Vaccine, Therapeutic – Collection: 248394

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 7

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 7

Primary Industries

  • Drugs
  • Vaccine
  • Therapeutic
  • Disease
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 248394

License Grant
The Licensor, government organization of England, grants the Licensee of England a nonexclusive worldwide license to use the Intellectual Property to develop, make, or have made, use, keep, sell, offer to sell, import and export Licensed Products, and to develop, make, have made, and use Anthrax Vaccine for the purpose of Licensor exercising the rights and licenses granted to Licensor with respect to Licensed Product.
License Property
Anthrax Vaccine shall mean protective antigen from Bacillus anthracis (anthrax) which is produced using recombinant technology.

Anthrax Vaccine Dose shall mean the quantity of a formulation containing Anthrax Vaccine given to an individual in a single immunization.

Licensed Product shall mean an Anthrax Vaccine Dose the manufacture, use, sale, keeping, importing or exporting of which would, in the absence of the license granted under this Agreement, constitute an infringement of the Patents or that uses other Intellectual Property.

The patent is for Expression System (Anthrax Immuuogenic Polypeptide), a UK Priority Patent Application.

Recombinant Bacillus Anthracis (Anthrax) Protective Antigen Vaccine containing Alum

The patent covers MOD Case P1454 Expression System.

Field of Use
These agreements allow for the licensing of certain patents and technology necessary to perform development of the rPA and rYP programs as required under the Company’s government contracts with the NIAID.

PharmAthene is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons.

IPSCIO Record ID: 249700

License Grant
The Licensor, government organization of England, grants the Licensee of England a nonexclusive worldwide license to use the Intellectual Property to develop, make, use, keep and sell or offer to sell Licensed Products.
License Property
The Licensed Product shall mean an Anthrax Vaccine Dose.

Recombinant Bacillus Anthracis (Anthrax) Protective Antigen Vaccine containing Alum

The patent covers MOD Case P1454 Expression System.

Field of Use
The license field is for disease vaccines.

IPSCIO Record ID: 248395

License Grant
The Licensor, government organization of England, grants the Licensee of England a nonexclusive worldwide license to use the Intellectual Property to develop, make, or have made, use, keep, sell, offer to sell, import and export Licensed Products.
License Property
The Intellectual Property shall mean the Patents and knowhow, technical information and materials, including but not limited to cell lines, owned by the Licensor necessary or useful to develop, manufacture, have manufactured, import use, keep, sell and offer to sell the Plague Antigen and/or Vaccine.

Licensed Product shall mean a Plague Antigen, and/or a Vaccine including but not limited to a Plague Vaccine Dose, the manufacture, use, sale, keeping, importing or exporting of which would, in the absence of the license granted under this Agreement, constitute an infringement of the Patents or that uses other Intellectual Property.

Plague Antigen shall mean individually each of the F1 antigen and V antigen of Yesinnia Pestis.

Plague Vaccine Dose shall mean the quantity of Vaccine given to an individual in a single dose.

Patents are for Plague Vaccines and Vaccine Compositions.

Field of Use
The field of use for any UK Government purpose or otherwise to the extent customary pursuant to standard UK Ministry of Defense contracting procedures.

IPSCIO Record ID: 248399

License Grant
The Licensor, government organization of England, grants the Licensee of England a nonexclusive license to use the Vaccine IP to further develop, manufacture, use, keep, import, export, supply or offer to supply, or, have a Partner manufacture, use, keep, import, export, supply or offer to supply, Plague Vaccine Doses to customers in performance of Supply Contracts.
License Property
Recombinant Yersinnia Pestis F1 and V (Plague) Protective Antigen Vaccine.

Plague Vaccine Dose shall mean a dose of recombinant protective antigen plague vaccine the manufacture, use, sale, keeping1 importing or exporting of which would, lo the absence of the license granted under this Agreement, constitute an infringement or actionable misuse of the Vaccine IP.

Patents are for Plague vacclnes and Vaccine Compositions.

Field of Use
The use in the United States is for the further development manufacture and supply of recombinant protective antigen plague vaccine doses.

The use beyond the United States is for inter alia the development of a prototype recombinant protective antigen plague vaccine and the production of trials doses thereof.

IPSCIO Record ID: 264264

License Grant
The Parties executed a worldwide exclusive sublicense agreement for the heat stabilization technology.
License Property
The heat stabilization technology, known as ThermoVax®. ThermoVax®:  The indication – Thermostability of aluminum adjuvanted vaccine for ricin (Vaccine Thermostability Platform)

ThermoVax® is a novel method of rendering aluminum salt, (known colloquially as Alum), adjuvanted vaccines stable at elevated temperatures. Alum is the most widely employed adjuvant technology in the vaccine industry. The value of ThermoVax® lies in its potential ability to eliminate the need for cold chain production, transportation, and storage for Alum adjuvanted vaccines. This would relieve the high costs of producing and maintaining vaccines under refrigerated conditions. Based on historical reports from the World Health Organization and other scientific reports, we believe that a meaningful proportion of vaccine doses globally are wasted due to excursions from required cold chain temperature ranges. This is due to the fact that most Alum adjuvanted vaccines need to be maintained at between 2 and 8 degrees Celsius (“C”) and even brief excursions from this temperature range (especially below freezing) usually necessitates the destruction of the product or the initiation of costly stability programs specific for the vaccine lots in question. ThermoVax® has the potential to facilitate easier storage and distribution of strategic national stockpile vaccines for ricin exposure in emergency settings.

The development of the vaccine programs currently is supported by our heat stabilization technology.  The focus is on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Proof-of-concept preclinical studies with ThermoVax® indicate that it is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions. These studies were conducted with our aluminum-adjuvanted ricin toxin vaccine, RiVax® and our aluminum-adjuvanted anthrax vaccine, VeloThrax®.

Field of Use
This agreement pertains to the drug industry for use in the fields of ricin and Ebola vaccines.

IPSCIO Record ID: 113052

License Grant
The company executed a worldwide exclusive license agreement with the the University for ThermoVax®, which is the subject of U.S. patent number 8,444,991 issued on May 21, 2013 titled “Method of Preparing an Immunologically-Active Adjuvant-Bound Dried Vaccine Composition.”
License Property
This patent and its corresponding foreign filings are licensed to us by the University and they address the use of adjuvants in conjunction with vaccines that are formulated to resist thermal inactivation. U.S. Patent 8,444,991 is expected to expire in December 2031. The license agreement also covers thermostable vaccines for biodefense as well as other potential vaccine indications.
Field of Use
This agreement pertains to the drug industry relating to vaccines.

The company is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.  The Company maintains two active business segments: BioTherapeutics and Vaccines/BioDefense.

The Company’s BioTherapeutics business segment is developing a first-in-class photodynamic therapy (SGX301) utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”), proprietary formulations of oral beclomethasone 17, 21-dipropionate (“BDP”) for the prevention/treatment of gastrointestinal (“GI”) disorders characterized by severe inflammation, including pediatric Crohn’s disease (SGX203) and acute radiation enteritis (SGX201), and it’s novel innate defense regulator (“IDR”) technology dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

The Company’s Vaccines/BioDefense business segment includes active development programs for RiVax™, its ricin toxin vaccine candidate, VeloThrax™, an anthrax vaccine candidate, OrbeShield®, a GI acute radiation syndrome (“GI ARS”) therapeutic candidate and SGX943, a melioidosis therapeutic candidate. The development of the vaccine programs currently supported by the heat stabilization technology, known as ThermoVax®, under existing and on-going government contract funding. With the government contract from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Company will attempt to advance the development of RiVax™ to protect against exposure to ricin toxin. The Company plans to use the funds received under the government contracts with the Biomedical Advanced Research and Development Authority (“BARDA”) and NIAID to advance the development of OrbeShield® for the treatment of GI ARS.

IPSCIO Record ID: 230788

License Grant
Licensor grants an exclusive license in the Territory, including the right to grant sublicenses, to manufacture, use, sell, offer for sale, and import Products under all its right, title and interest in the Patent Rights.
License Property
Product means any animal vaccine or therapeutic agent the manufacture, use, sale, offer for sale or import of which would infringe any Valid Claim within Patent Rights in the absence of a license.

Food Safety Product means a Product to eliminate or reduce organisms associated with food borne disease in livestock.

The licensed property include patents for Immunogenic compositions comprising avirulent derivatives of Salmonella typhi with mutations in cya, crp and cdt, Method of maintaining a desired recombinant gene in a genetic population of cells, Avirulent Salmonella containing genes encoding gamete specific antigen useful as vaccine for diminishing or preventing fertility, Method of vaccination of newly hatched poultry, Recombinant vaccines comprising immunogenic attenuated bacteria having RpoS  phenotype, Methods of producing and using virulence attenuated poxRmutant bacteria, Recombinant bacterial system with environmentally limited viability, Live attenuated Salmonella vaccines to control avian pathogens, Regulated Antigen Delivery Systems, and, various patents for Avirulent microbes.

Field of Use
The field of use Area means research, development and commercialization with respect to animal vaccines and therapeutic agent as further described in the Research Plan.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.